Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clonal architecture and growth dynamics of ibrutinib-resistant CLL: Oligoclonal BTK/PLCG2 mutations and emerging non-BTK/PLCG2 drivers

View Full Paper
Ask AI
Bookmark
Share

Authors

LVLauren VaughnPNPia Nierman

Discussion

Loading...

Member takes

Overview

Phase 2 study examines BTK mutations and progression-free survival in 84 CLL patients, highlighting resistance factors.

Key Points

  • Ibrutinib resistance is linked to BTK mutations detected in 89.3% of patients with progressive disease.
  • The median progression-free survival was 86.6 months, and 46.4% experienced disease progression.
  • Observational analysis using whole-exome sequencing revealed complex clonal dynamics in peripheral blood samples.
  • Emerging non-BTK/PLCG2 clones also showed significant growth, emphasizing the need for further exploration of resistance drivers.

Cite This Study

Vaughn et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8afhttps://doi.org/10.1182/blood-2025-5654
View Full Paper
Ask AI
Bookmark
Share